Regeneron Pharmaceuticals Inc (NAS:REGN)
$ 968 12.24 (1.28%) Market Cap: 106.66 Bil Enterprise Value: 97.49 Bil PE Ratio: 28.60 PB Ratio: 3.95 GF Score: 94/100

Regeneron Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 03:00PM GMT
Release Date Price: $305.85 (+0.40%)
Ying Huang
BofA Merrill Lynch, Research Division - Director in Equity Research

(technical difficulty)

to Day 2 of the Bank of America Merrill Lynch Conference. My name is Ying Huang and I'm the Large Cap U.S. Biotech Analyst.

I'm very pleased to announce our next presenting company, Regeneron Pharmaceuticals. With us, we have President, CEO and founder, Dr. Len Schleifer; also we have Bob Landry, Chief Financial Officer, with us.

So we're going to use the fireside chat format, and we'll just go into the Q&A.

First of all, let me welcome both Len and Bob to Vegas. Thanks for coming again.

Robert E. Landry
Regeneron Pharmaceuticals, Inc. - Executive VP of Finance & CFO

So Ying, let me make some forward-looking statements for those that are on webcast.

We will be making forward-looking statements and it contains risks and uncertainties. Certainly, you can go to our recently filed 10-Q, which outlines all the risks and uncertainties within that disclosure. Okay. Thanks.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot